Molecular changes during AT/RT progression associated with epithelial–mesenchymal transition and extracellular matrix changes - Takeaways - MDSpire

Molecular changes during AT/RT progression associated with epithelial–mesenchymal transition and extracellular matrix changes

  • By

  • Lea Altendorf

  • Anton Althammer

  • Rajanya Roy

  • Karoline Hack

  • Flavia W. de Faria

  • Arend Koch

  • Vanessa Thaden

  • Melanie Schoof

  • Martin U. Schuhmann

  • Peter Hauser

  • Pascal D. Johann

  • Martin Hasselblatt

  • Michael C. Frühwald

  • Kornelius Kerl

  • Ulrich Schüller

  • July 1, 2026

  • 0 min

Share

  • 1

    AT/RT are aggressive CNS tumors in young children with a median overall survival of 9 to 17 months, depending on risk groups.

  • 2

    95% of AT/RT patients have SMARCB1 mutations, while a rare subset has SMARCA4 mutations, both linked to tumor suppression.

  • 3

    AT/RT patients typically undergo surgery and chemotherapy, but radiotherapy is rarely recommended for those under 3 years.

  • 4

    The study identifies transcriptomic differences in paired primary and recurrent AT/RT tumors, highlighting therapy-resistant cells.

  • 5

    Increased extracellular matrix remodeling and epithelial-mesenchymal transition are associated with therapy resistance in AT/RT.

Original Source(s)

Molecular changes during AT/RT progression associated with epithelial–mesenchymal transition and extracellular matrix changes

  • by Lea Altendorf, Anton Althammer, Rajanya Roy, Karoline Hack, Flavia W. de Faria, Arend Koch, Vanessa Thaden, Melanie Schoof, Martin U. Schuhmann, Peter Hauser, Pascal D. Johann, Martin Hasselblatt, Michael C. Frühwald, Kornelius Kerl, Ulrich Schüller

  • July 1, 2026

Related Content

Artificial intelligence for triple-negative breast cancer from imaging to multi-omics

Systematic pan-cancer analysis reveals context-dependent prognostic and immunological roles of WDR1 with divergent effects in renal and gastric cancers

Development and application of a prognostic model based on radiomics and artificial intelligence for patients with lung adenocarcinoma brain metastasis